Moleculin Biotech, Inc. (LON:0K2H)
0.5529
+0.0194 (3.64%)
At close: Jul 11, 2025
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-1.06M GBP
Market Cap
11.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
HSBC Holdings | 211,304 |
Shell | 96,000 |
Unilever | 115,964 |
British American Tobacco p.l.c. | 48,989 |
Rolls-Royce Holdings | 42,400 |
Rio Tinto Group | 60,000 |
RELX PLC | 36,400 |
Moleculin Biotech News
- 20 days ago - Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga
- 26 days ago - Moleculin Biotech prices $5.9M public offering; shares down about 47% - Seeking Alpha
- 26 days ago - Moleculin Announces $5.9 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 4 weeks ago - Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewsWire
- 5 weeks ago - Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 5 weeks ago - Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) - GlobeNewsWire
- 6 weeks ago - Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewsWire